XORTX Therapeutics Inc.
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
XORTX Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements XORTX Therapeutics filed with the SEC
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Item 1: Name and Address of Company
EX-99.2 to Form 6-K
IR Agency LLC (the “Consultant” or
EX-99.1 to Form 6-K
XORTX Announces Termination and Postponement of Investor Relations Program
EX-99.1 to Form 6-K
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
For the six months ended June 30, 2026
EX-99.2 to Form 6-K
I, Allen Davidoff, Co-Chief Executive Officer of XORTX Therapeutics Inc.,
EX-99.3 to Form 6-K
For more information, please contact:
EX-99.1 to Form 6-K
For more information, please contact:
EX-99.1 to Form 6-K
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
EX-99.1 to Form 6-K
XORTX Announces Closing of US$5 Million Public Offering
EX-99.1 to Form 6-K
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
For the three months ended March 31, 2026
EX-99.2 to Form 6-K
I, Allen Davidoff, Chief Executive Officer of XORTX Therapeutics Inc.,
EX-99.3 to Form 6-K
XORTX Announces US$5 Million Public Offering
EX-99.1 to Form 6-K
XORTX Meets Nasdaq Continued Listing Requirements
EX-99.1 to Form 6-K
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
EX-99.1 to Form 6-K
XORTX Confirms Effective Date of Share Consolidation
EX-99.1 to Form 6-K
XORTX Announces Results of Annual and Special Meeting of Shareholders
EX-99.1 to Form 6-K
(Section 11.3 of National Instrument 51-102)
EX-99.1 to Form 6-K
XORTX Announces Change of Effective Date of Share Consolidation
EX-99.1 to Form 6-K
For more information, please contact:
EX-99.1 to Form 6-K
3710 – 33 rd Street NW, Calgary, Alberta, Canada T2L
EX-99.1 to Form 6-K
ANNUAL & SPECIAL MEETING OF THE HOLDERS OF COMMON SHARES
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
As at and for the years ended
EX-99.1 to Form 6-K
For the year ended December 31, 2025
EX-99.2 to Form 6-K
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
For the nine months ended September 30, 2025
EX-99.2 to Form 6-K
I, Allen Davidoff, Chief Executive Officer of XORTX Therapeutics Inc.,
EX-99.3 to Form 6-K